Brain serotonin plays a crucial role in the regulation of food intake and body weight homeostasis. Previous data suggest an interaction with corticotropin-releasing hormone (CRH). To further examine the interaction between these neurotransmitters, the selective serotonin reuptake-inhibitor (SSRI) fluvoxamine was given intraperitoneally in fa=fa Zucker rats with and without the CRH-receptor-antagonist a-helical CRH administered intracerebroventriculary (i.c.v.). The saline treated animals gained weight. Fluvoxamine led to a significant weight loss while not affecting food intake. Furthermore, insulin levels in this animal model were reduced following fluvoxamine administration. These effects were antagonized by a-helical CRH and are thus most likely mediated via CRH or CRH-like peptides.
Introduction
Selective serotonin reuptake inhibitors (SSRI) are commonly used as drug treatment in depressive disorders. These drugs are well known to centrally affect food intake and body weight homeostasis. This is in accordance with experimental data, demonstrating strong anorectic properties of serotonin when injected into the paraventricular nucleus (PVN) and other hypothalamic areas. 1, 2 In the present study we focussed on anorectic properties of the ssri fluvoxamine, which is more specific for serotonin when compared to other compounds of this group of drugs, eg fluoxetine, exerting less effects on the reuptake of noradrenaline. 3 Previous data suggest that, within the PVN, serotonin and corticotropin releasing hormone (CRH) interact to alter food intake and enhanced CRH synthesis has been shown in this particular nucleus following serotonin injection. 4, 5 In addition, a stimulating effect of D-fenfluramine, a serotoninreleasing agent, on neuronal activation of CRH expressing cells in the PVN has been demonstrated. 6 CRH clearly possesses anorectic properties, when injected centrally. 7 A causal relationship between the neurotransmitter serotonin and the neuropeptide CRH has, as yet, not been demonstrated. In addition to its anorectic actions, CRH stimulates brown adipose tissue metabolism via activation of the sympathetic nervous system in rodents, when applied centrally, 8, 9 potentially causing an increase in energy expenditure.
In fa=fa Zucker-rats, CRH 2 -receptor mRNA is reduced in the ventromedial hypothalamus (VMH), suggesting a possible involvement of CRH-neurons in the reduced energy expenditure in this genotype; 10 in addition the hyperinsulinemia in these animals, which is ascribed to an increased activity of vagal efferents to the pancreas, 11 is reduced after local application of CRH to the VMH.
This study was aimed at further investigating the nature of brain serotonin and CRH interaction in the control of body weight, which has not been studied before in a long-term in vivo experiment.
Methods
Chloral hydrate and a-helical CRH were purchased from Sigma Chemie (Deisenhofen, Germany). Fluvoxamine maleate was obtained from Solvay Duphar. Insulin was determined by Insulin RIA 100 from Pharmacia and Upjohn Diagnostics AB, Sweden.
Male homozygote fa=fa rats from Harlan-Winkelmann, Borchem, Germany were studied. At the beginning of the experiment, the animals were 12 weeks old and weighed between 300 and 400 g. The animals were kept in single cages at a constant room temperature of 23 C under a 12 h light and dark cycle and were allowed to adapt to the housing conditions prior the surgery for at least 4 days. The dosages of a-helical CRH and fluvoxamine have been shown to be effective by other authors 12 and have been tested by us in a pilot study.
The animals were assigned to four experimental groups: group 1 -0.5 ml saline i.p. and 10 ml saline i.c.v., n ¼ 7; group 2 -fluvoxamine i.p. (25 mg=kg body weight in 0.5 ml saline) and a-CRH i.c.v. (25 mg in 10 ml saline), n ¼ 5; group 3 -fluvoxamine i.p. (25 mg=kg body weight in 0.5 ml saline) and 10 ml saline i.c.v., n ¼ 6; and group 4 -0.5 ml saline i.p. and a-CRH i.c.v. (25 mg in 10 ml saline), n ¼ 4.
Puncture of the femoral artery and implantation of a catheter were performed for blood sampling. Chloral hydrate in a dosage of 0.4 g per kg body weight was given i.p. for anesthesia. During surgery the body temperature was maintained by a regulated heat pad. A glass capillary was placed into the left lateral ventricle for injection purposes using a stereotaxic instrument. The required coordinates were taken from the Paxinos and Watson atlas. 13 On the first postoperative day, the experimental animals were placed in a special cage providing free access to the rat without disturbance.
After a 30 min period of adaptation, a serum sample for the determination of baseline insulin value was taken and the i.p. injection was performed. After the injection, blood samples were drawn at 30, 60, 90 and 120 min. The drawn volume was replaced with saline immediately after each collection; the total amount of blood taken did not exceed 1.5 ml in each animal. The samples were centrifuged immediately; serum was collected and frozen at 770 C until analysis of insulin.
Food intake and body weight of the animals were documented in the following 7 days. The body weight of the rats was measured on the day of surgery and once a day between 12 am and 2 pm during the observation period. The experimental animals received the i.p. and i.c.v. treatment at 8 am for seven consecutive days. The rats were killed between 1:30 and 2:30 pm, in the middle of the light phase of the light= dark cycle.
Statistical analyses was performed by using SPSS, version 8.0 for windows. ANOVA for repeated measures was performed on raw data and a 2Â2 ANOVA was performed on normalized data. Tukey's t-test was used as post hoc test for comparisons after the repeated measures ANOVA. The cumulative food intake was similar in groups 1 -3 (group 1; 42.55 AE 8.11 g; group 2, 68.35 AE 33.98 g; group 3, 56.82 AE 26.97 g), while it was found to be lower in group 4 (14.61 AE 6.0 g). The overall body weight gain to food intake ratio in the different groups was significantly different from each other: group 1, 0.5 AE 0.2, group 2, 0.2 AE 0.2; group 3,70.4 AE 0.3; and group 4, 0.3 AE 0.1, respectively. Despite a cumulative food intake of 56.8 AE 27.0 g in the group receiving fluvoxamine alone, this ratio was clearly lower than in the other groups (a ¼ 0.048 -0.002). Furthermore, a significant interaction of peripheral (fluvoxamine=saline) and central (a-CRH=saline) treatment was observed within all groups.
Results
After the administration of fluvoxamine i.p. combined with saline i.c.v. a decrease in serum insulin by approximately 30% was observed (Table 1 ) when compared to control animals receiving saline i.p. and i.c.v. Following the combined administration of fluvoxamine i.p. and ahelical CRH i.c.v., the effects of the ssri were clearly diminished and serum insulin remained stable at the baseline value. The administration of saline i.p. and a-helical CRH i.c.v. had no effect on serum insulin concentrations.
Discussion
These data demonstrate that body weight changes were strongly affected by fluvoxamine, although there were only minor effects on food intake. Because these effects are abolished, at least in part, by the central administration of a-helical CRH, this is strongly suggestive of an involvement of central CRH or other CRH-like peptides such as urocortin in the mechanism of fluvoxamine actions. This is also supported by data showing that the central administration of CRH prevents excessive weight gain in fa=fa Zucker rats. 8 Interestingly an activation of CRH expressing cells in the PVN has been observed following application of D-fenfluramine. 6 Although the effects of exogenous CRH or different stress-paradigms on neuronal activity, autonomic system and behavior may be blocked by centrally administred ahelical CRH, 14 -17 the receptor-antagonist alone has been found to be without intrinsic activity on food intake and body weight. 18, 19 Although we did observe a small reduction in food intake in the group of animals treated with a-helical CRH, possibly due to an intrinsic activity of the agonist, body weight was unaffected. Compared to control animals (saline i.p.=saline i.c.v.), rats receiving a combination of fluvoxamine i.p.=saline i.c.v. remarkably lost weight despite unaltered food intake, thus indicating an increased energy expenditure similar to the actions of fenfluramine. This is reflected by the negative body weight gain=food intake ratio. It has been speculated that the thermogenic actions of fenfluramine are mediated via CRH, 19 which itself acts in the medial preoptic area of the hypothalamus to stimulate brown adipose tissue (BAT) metabolism through the sympathetic nervous system. 20 The basal hyperinsulinemia of the fa=fa Zucker rats has been explained by an enhanced parasympathetic outflow to the endocrine pancreas 2,20 and could be reduced by i.c.v. administration of CRH. 13 Our data clearly support the notion that fluvoxamine's effects on insulin secretion are mediated through CRH since they were abolished by ahelical CRH at least in part.
In summary the results of our experiments clearly suggest, that CRH or CRH-like peptides are strongly involved in the serotoninergic regulation of body weight. *Statistically significant when compared with baseline of the respective group at time 0 (P < 0.05).
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